This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Last revision Both sides next revision | ||
dag3 [2022/02/22 15:02] bas [Collected samples] |
dag3 [2022/05/13 09:41] trynke |
||
---|---|---|---|
Line 10: | Line 10: | ||
===== Subcohort ===== | ===== Subcohort ===== | ||
- | A total of 9500 participants were included in the DAG3 dataset: | + | A total of +-9500 participants were included in the DAG3 dataset: |
* 700 were [[children]] aged 8-17 years | * 700 were [[children]] aged 8-17 years | ||
* 400 participants were also included in the ([[DEEP]]) dataset | * 400 participants were also included in the ([[DEEP]]) dataset | ||
Line 16: | Line 16: | ||
* ~9000 participants were genotyped in the [[UGLI]] project. | * ~9000 participants were genotyped in the [[UGLI]] project. | ||
- | Metagenomic sequencing of the Lifelines DAG3 samples is underway to assess taxonomy, strain diversity and functionality. Uniquely, not only are all individuals fully genotyped but glycerol aliquots of their microbiota are also stored to enable bacterial culture for further functional studies. Lifelines DAG3 will have the power to study host-microbe interactions and will also allow studies to move from association to causality ((Doestzada, M., Vich Vila, A., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., ... Fu, J. | + | Metagenomic sequencing of the Lifelines DAG3 samples was performed to assess taxonomy, strain diversity and functionality. Uniquely, not only are all individuals fully genotyped but glycerol aliquots of their microbiota are also stored to enable bacterial culture for further functional studies. Lifelines DAG3 will have the power to study host-microbe interactions and will also allow studies to move from association to causality ((Doestzada, M., Vich Vila, A., Zhernakova, A., Koonen, D. P. Y., Weersma, R. K., Touw, D. J., ... Fu, J. |
(2018). Pharmacomicrobiomics: A novel route towards personalized medicine? Protein & cell, 9(5).)). | (2018). Pharmacomicrobiomics: A novel route towards personalized medicine? Protein & cell, 9(5).)). | ||
Line 64: | Line 64: | ||
* 2482 incomplete diaries (i.e. may miss one or more days) | * 2482 incomplete diaries (i.e. may miss one or more days) | ||
- | * Multiple samples from a single participant | + | *Multiple samples from a single participant |
+ | |||
+ | ===== Papers based on DAG3 ===== | ||
+ | * Gacesa, R et al. (2022) Environmental factors shaping the gut microbiome in a Dutch population. Nature 604, 732–739 |